| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NA | Pemigatinib | Pemazyre | 4.5mg, 9mg, 13.5mg | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3 | Yes | 2020 | In Use | |||
| NA | Nilotinib | Tasigna | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2007 | In Use | |||
| NA | Purixan | Purixan | 20mg | Chemotherapy | Antimetabolite | Purine | Yes | 2014 | In Use | |||
| J9351 | Topotecan | Hycamtin | 0.1 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | No | 1996 | Jan 1, 2011 | In Use | ||
| Tovorafenib | Ojemda | 25mg, 100mg | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | Yes | 2024 | In Use | ||||
| NA | ixazomib | Ninlaro | 4 mg | Chemotherapy | Proteasome Inhibitor | 20S | Yes | 2015 | In Use | |||
| NA | Fedratinib Hydrochloride | Inrebic | 100mg | Chemotherapy | Enzyme Inhibitor | JAK2, FLT3 | Yes | 2019 | In Use | |||
| J9307 | Pralatrexate | Folotyn | 1 mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2009 | Jan 1, 2011 | In Use | ||
| NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| J9207 | ixabepilone | Ixempra | 1mg | Chemotherapy | Antitumor Antibiotic | Epothilones | No | 2007 | Jan 1, 2009 | In Use | ||
| N/A | Dordaviprone | MODEYSO | 125mg | Chemotherapy | Protease Activator | ClpP, dopamine D2 | Yes | 2025 | In Use | |||
| NA | Pirtobrutinib | Jaypirca | Multiple | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Yes | 2023 | In Use | |||
| J9380* | Vincristine | Oncovin, Vincasar PFS | 5 mg | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | No | 1963 | Jan 1, 1994 | Dec 31, 2010 | No Longer Used | |
| NA | Brigatinib | Alunbrig | 30 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2017 | In Use | |||
| J9120 | Dactinomycin | Cosmegen | 0.5 mg | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | No | 1964 | Jan 1, 1984 | In Use | ||
| NA | Zanubrutinib | Brukinsa | 80mg | Chemotherapy | Tyrosine Kinase Inhibitor | BTK | Yes | 2019 | In Use | |||
| J9267 | Paclitaxel | Taxol | 1 mg | Chemotherapy | Antimitotic Agent | Taxane | No | 1992 | Jan 1, 2015 | In Use | ||
| NA | Ibrutinib | Imbruvica | 140 mg | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Yes | 2014 | In Use | |||
| J9255 | Methotrexate (Accord) | Methotrexate | 50mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2014 | Dec 7, 2023 | In Use | ||
| NA | Niraparib | Zejula | 100 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
| J9352 | Trabectedin | Yondelis | 0.1mg | Chemotherapy | Alkylating Agent | Natural Product | No | 2015 | Jan 1, 2017 | In Use | ||
| NA | Trametinib | Mekinist | 0.5 mg | Chemotherapy | MEK Inhibitor | BRAF | Yes | 2013 | In Use | |||
| C9078 | Trilaciclib | Cosela | 1mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDX 4/6 | No | 2021 | Jul 23, 2021 | Sep 27, 2021 | No Longer Used | |
| NA | Vemurafenib | Zelboraf | 240 mg | Chemotherapy | Enzyme Inhibitor | BRAF | Yes | 2011 | In Use | |||
| J9370 | Vincristine | Oncovin, Vincasar PFS | 1 mg | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | No | 1963 | Jan 1, 1986 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home